Steven Campbell, MD
Pulmonary Disease · Crestview Hills, KYNPI 1861768988
Payments from drug & device makers
Across 252 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$803
- GSK$714
- AstraZeneca$623
- Boehringer Ingelheim$544
- Insmed, Inc.$410
- Bayer$330
- plus $2K from 27 others
What the payments were for
- Consulting fees$2004%
- Food & beverage$4,73887%
- Education$4799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 42 | $803 |
| GSK | 64 | $714 |
| AstraZeneca | 20 | $623 |
| Boehringer Ingelheim | 28 | $544 |
| Insmed, Inc. | 13 | $410 |
| Bayer | 4 | $330 |
| Sanofi | 7 | $193 |
| Grifols USA, LLC | 10 | $182 |
| Mylan Specialty L.p. | 9 | $175 |
| Genentech USA, Inc. | 3 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $133 |
| Covidien LP | 1 | $123 |
| Mallinckrodt Hospital Products Inc. | 2 | $118 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| United Therapeutics Corporation | 5 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Mallinckrodt Enterprises LLC | 1 | $96 |
| Merck | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 6 | $84 |
| Vifor Pharma, Inc. | 3 | $64 |
| Pulmonx Corporation | 1 | $50 |
| Baxter Healthcare | 2 | $27 |
| Harmony Biosciences LLC | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Novartis | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Inogen, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $19 |
| Pfizer | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| AbbVie | 1 | $13 |
| Gilead | 1 | $12 |
| Fisher & Paykel Healthcare Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$200
- FASENRA$124
- superDimension$123
- IMFINZI$121
- ACTHAR$103
How this compares
$5,417 in reported general payments places this provider in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 65 | $1,502,685 |
| Tyvaso DpiTreprostinil | 62 | $1,488,480 |
| OpsumitMacitentan | 58 | $725,912 |
| AdempasRiociguat | 30 | $419,439 |
| WinrevairSotatercept-Csrk | 15 | $327,936 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 287 | $243,526 |
| Orenitram ErTreprostinil Diolamine | 36 | $234,774 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 251 | $197,971 |
| Dupixent PenDupilumab | 14 | $49,851 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $24,986 |
| Spiriva RespimatTiotropium Bromide | 41 | $22,483 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $20,888 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $17,347 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $14,166 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $13,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $803 | $2,228,598123 claims |
| BayerAdempas | $330 | $419,43930 claims |
| MerckWinrevair | $85 | $327,93615 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $714 | $285,391376 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $623 | $218,858326 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $544 | $53,73791 claims |
| PfizerEliquis | $15 | $6,99412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Crestview Hills
- Neal MoserCrestview Hills$18K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.